{"analyses":[{"ciNumSides":"TWO_SIDED","groupIds":["OG000","OG002"],"nonInferiorityType":"SUPERIORITY_OR_OTHER_LEGACY","pValue":"0.002","pValueComment":"a priori p-value significance threshold: 2-sided ≤0.05","statisticalMethod":"Wilcoxon (Mann-Whitney)"},{"ciNumSides":"TWO_SIDED","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER_LEGACY","pValue":"0.004","pValueComment":"a priori p-value significance threshold: 2-sided ≤0.05","statisticalMethod":"Wilcoxon (Mann-Whitney)"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"-15.0","upperLimit":"0.0","value":"-8.0"},{"groupId":"OG001","lowerLimit":"-40.0","upperLimit":"-15.0","value":"-25.5"},{"groupId":"OG002","lowerLimit":"-40.0","upperLimit":"-15.0","value":"-27.0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"172"},{"groupId":"OG001","value":"172"},{"groupId":"OG002","value":"175"}],"units":"Participants"}],"description":"Participants reported the duration of their morning joint stiffness (MJS) in hours and minutes. The participants were asked about their duration of morning joint stiffness on the day prior to the study visit to capture actual symptoms, since the participant may have had an atypical morning routine on that day. If morning joint stiffness duration was longer than 12 hours (720 minutes), it was truncated to 720 minutes for statistical presentations and analyses. A decrease in duration of morning joint stiffness indicated an improvement in the participant's condition.","dispersionType":"95% Confidence Interval","groups":[{"description":"Placebo administered PO QD through Week 24. Participants continued to take background cDMARD therapy throughout study.","id":"OG000","title":"Placebo"},{"description":"Baricitinib 2 mg administered PO QD through Week 24. Participants continued to take background cDMARD therapy throughout study.","id":"OG001","title":"Baricitinib 2 mg"},{"description":"Baricitinib 4 mg administered PO QD through Week 24. Participants continued to take background cDMARD therapy throughout study.","id":"OG002","title":"Baricitinib 4 mg"}],"paramType":"MEDIAN","populationDescription":"mITT population includes all randomized participants who received at least 1 dose of the study drug. Participants were analyzed according to the study drug to which they were randomized. Missing values due to discontinuation of study or drug, rescue, or missing data were imputed using mLOCF.","reportingStatus":"POSTED","timeFrame":"Baseline, Week 24","title":"Change From Baseline in Duration of Participant Reported Outcome - Morning Joint Stiffness","type":"SECONDARY","unitOfMeasure":"Minutes"}